Fondaparinux Sodium

CHEMBL1200644 Phase 4 Aprobado Oligosaccharide

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1728.1 g/mol

LogP

—

Phase

4

This sodium salt form of fondaparinux is an injectable anticoagulant that selectively inhibits Factor Xa in the blood clotting cascade. It is used to prevent and treat venous thromboembolism and is also used in the management of acute coronary syndromes.

Peso molecular

1728,1000 g/mol

TPSA

901,00 Å²

Áreas terapéuticas

Cáncer colorrectal Cáncer de mama Cáncer de ovario Cáncer de páncreas Cáncer de próstata Cáncer de pulmón de células no pequeñas Cáncer de tiroides Cáncer de vejiga Enfermedad cardiovascular Fibrilación auricular Obesidad Trombosis venosa profunda / Embolia pulmonar

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

InChI

InChI=1S/C31H53N3O49S8.10Na/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56;;;;;;;;;;/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68);;;;;;;;;;/q;10*+1/p-10/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-;;;;;;;;;;/m1........../s1

Molecular Formula

C31H43N3Na10O49S8

HBD / HBA

9 / 52

Enlaces Rotables

20

Átomos Pesados

101

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

This sodium salt form of fondaparinux is an injectable anticoagulant that selectively inhibits Factor Xa in the blood clotting cascade. It is used to prevent and treat venous thromboembolism and is also used in the management of acute coronary syndromes.

Yes, Fondaparinux Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Oligosaccharide.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200644. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 636380. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

¿Busca información accesible para el paciente?

Fondaparinux Sodium en PillFYI

Estructura

Datos Rápidos

Fórmula: C31H43N3Na10O49S8
Sinónimos: 1

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.